Why Oscar Health's 'Great Quarter' Isn't What It Looks Like

Why Oscar Health's 'Great Quarter' Isn't What It Looks Like

Oscar Health looks like a screaming buy — growing revenue, growing members, positive free cash flow. So why does the market keep discounting it? We ran the numbers.

Oscar Health (OSCR) just posted strong headline numbers: member growth accelerating past 3 million, revenue climbing, free cash flow positive. Health insurers don't get valued like typical growth stocks — and free cash flow is one of the most misleading metrics you can use here.

In this episode, we break down why insurance float — not free cash flow — is the real driver of Oscar's balance sheet, how the medical loss ratio (MLR) caps profitability by regulation, and why receivables and payables to CMS matter more than most investors realize. We also walk through two reverse DCF scenarios on GAAP earnings per share — a 10-year model and a more aggressive 3-year model — to see what growth rate the market is actually pricing into OSCR today.

Think of it as a masterclass in valuing any financials-driven business — insurance, banks, specialty finance — differently than you'd value a software or semiconductor company. We also give a first look at the new investment thesis checklist tool and segment/KPI dashboard inside Semiconductor Insider.

TIMESTAMPS0:00 - Why Oscar Health Looks Cheap (And Why That's Misleading)1:04 - Revenue, Member Growth & Free Cash Flow Overview2:00 - The Problem: Free Cash Flow Isn't Real Cash Flow Here2:40 - Medical Loss Ratio Explained: The 80% Rule3:03 - Insurance Float 101 (The Berkshire Hathaway Playbook)4:38 - Reading the Balance Sheet: Premiums, Payouts & SG&A5:24 - CMS Receivables & Payables: The Hidden ACA Liability7:00 - Reverse DCF: 10-Year vs. 3-Year Growth Scenarios9:07 - Building a Custom Investment Thesis Checklist10:40 - Final Takeaway: How to Actually Value Oscar Health

If you want the reasoning behind more names like this one, Semiconductor Insider covers the process in more depth. Get access to all our research, weekly live Q&A events, and a growing set of tools to build your process: https://www.chipstockinvestor.com

All our socials: https://linktr.ee/chipstockinvestor

If you're getting value from the show, follow so you don't miss the next one.

Disclosure: Some links above are affiliate links. If you buy something through them, we might earn a little coffee money — thanks for helping us (Kasey) fuel our caffeine addiction.

Content in this episode is for general information or entertainment only and is not specific or individual investment advice. Forecasts and information presented may not develop as predicted, and there is no guarantee any strategies presented will be successful. All investing involves risk, and you could lose some or all of your principal. CSI doesn't own shares of Oscar Health.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(492)

Twist Bioscience Soared — We're Still Not Buying

Twist Bioscience Soared — We're Still Not Buying

Twist Bioscience (TWST) just had a massive run-up after Anthropic's protein design results put its DNA synthesis platform in the spotlight. Here's what's really driving the stock — and whether it's st...

17 Syys 14min

The Fastest-Growing Chip Stock Is Also the Most Hated

The Fastest-Growing Chip Stock Is Also the Most Hated

We compare Credo (CRDO) against Broadcom (AVGO), Marvell (MRVL), and Astera Labs (ALAB) on revenue growth, gross margin, operating margin, and free cash flow margin — four fabless companies selling in...

15 Syys 13min

AI Data Center Spending Means Good Times For Semiconductors Continue -- Oracle ORCL Stock Analysis

AI Data Center Spending Means Good Times For Semiconductors Continue -- Oracle ORCL Stock Analysis

We break down the takeaways from Oracle's (ORCL) Q1 fiscal 2027 earnings call — what to expect through 2026 and into 2027–2028 as hyperscaler CapEx stays high but is set to slow in growth by 2027, and...

14 Syys 12min

Nvidia's Biggest Acquisition Ever: $12.9B for Hugging Face (Can It Survive Regulators?)

Nvidia's Biggest Acquisition Ever: $12.9B for Hugging Face (Can It Survive Regulators?)

Nvidia just proposed its largest acquisition ever — $12.9 billion for Hugging Face. But regulators in the US, EU, and China may have other plans.Nvidia has announced plans to acquire Hugging Face, the...

10 Syys 15min

Pure Storage Is Now Everpure — and Free Cash Flow Just Went Negative (P Stock)

Pure Storage Is Now Everpure — and Free Cash Flow Just Went Negative (P Stock)

Pure Storage just rebranded to Everpure — and in the same stretch, free cash flow went negative 20% in a single quarter. Here's what's really going on.Pure Storage has officially rebranded as Everpure...

10 Syys 19min

Procept Is Down 80% and the Tech Works — So Why Won't We Buy PRCT?

Procept Is Down 80% and the Tech Works — So Why Won't We Buy PRCT?

Procept BioRobotics is down roughly 80% from its 2025 highs but the technology behind its Aquablation system genuinely works. So why won't we put PRCT in our portfolio?Procept (PRCT) has one of the mo...

10 Syys 28min

Palo Alto Is Up 1,400% in a Decade — What Comes Next? (PANW FY2026)

Palo Alto Is Up 1,400% in a Decade — What Comes Next? (PANW FY2026)

Palo Alto Networks (PANW) has been flying high into the end of FY2026. After a decade-long 1,400% run — capped by a broader cybersecurity rally following the Anthropic "Mythos moment" in early 2026 — ...

2 Syys 14min

Suosittua kategoriassa Liike-elämä ja talous

sijotuskasti
vallattomat
psykopodiaa-podcast
mimmit-sijoittaa
rss-rahapodi
rss-oivalluksia-rahasta-elamasta
ostan-asuntoja-podcast
oppimisen-psykologia
lakicast
rss-paasipodi
rss-alanvaihtajat
rss-porssipodi
rss-karon-grilli
rss-startup-ministerio
rss-inderes
rss-siksi-viestinta
rahapuhetta
hyva-paha-johtaminen
rss-pinnan-alle
rss-sami-miettinen-neuvottelija